Abstract 248P
Background
Carcinoma cervix is a leading cause of cancer in Indian females where 15%–60% of the cases eventually metastasize. This is a retrospective review of outcome of metastatic carcinoma cervix patients treated in Kidwai Memorial institute, Bangalore from 2016-2018.
Methods
We retrospectively analysed our data between October 2016 and September 2018 to identify the cases of metastatic carcinoma cervix and tried to analyse their outcomes with platinum-based chemotherapy.
Results
138 cases of metastatic carcinoma cervix were identified during these 2 years. Median age was 49 years (29-73 years). 27(19.5%) patients were HIV+. 39(28.8%) were upfront metastatic & 99(71.8%) were recurrent metastatic. Most common histology was Squamous cell carcinoma, grade II (50%). Nodal recurrence was seen in 108 (78.2%) patients, with most common being pelvic lymph nodes (69.5%) followed by retroperitoneal lymphadenopathy (36.9%) & supraclavicular lymphadenopathy (19.5%). Distant recurrence seen in 93 patients (67.3%) & most common site was lung (54.3%) followed by liver(45.6%), adrenal(4.3%), bone(6.5%) & ascites(8.6%). Nodal-only recurrence was seen in 45 (32.6%) patients. 129(93.4%) patients received palliative chemotherapy as follows- Paclitaxel/Carboplatin (82.6%), Paclitaxel/Cisplatin (6.5%), Gemcitabine/Carboplatin (2.1%), Paclitaxel/Carboplatin/Bevacizumab (2.1%). Overall response rates were 32.6% (CR-4.3%). Median progression-free survival and overall survival (OS) were 6 months and 13 months, respectively.
Conclusions
Nodal-only metastasis did not show favourable outcome as compared to visceral metastasis. However, disease remains aggressive and poor survival demands further research into newer molecules & regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract